Interfacial inhibitors: Targeting macromolecular complexes

Nature Reviews Drug Discovery

Volumn 11, Issue 1, 2012, Pages 25-36

  Pommier, Yves ^a   Marchand, Christophe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; AMSACRINE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CIPROFLOXACIN; COLCHICINE; DAUNORUBICIN; DOXORUBICIN; ELVITEGRAVIR; EPIRUBICIN; EPOTHILONE A; ETOPOFOS; ETOPOSIDE; GEMIFLOXACIN; IDARUBICIN; IRINOTECAN; LEVOFLOXACIN; MITOXANTRONE; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OXOLINIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RALTEGRAVIR; RAZOXANE; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84855347756     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3404     Document Type: Review

References (84)

1. Conti, C. et al. Replication fork velocities at adjacent replication origins are coordinately modified during DNA replication in human cells. Mol. Biol. Cell 18, 3059-3067 (2007). (Pubitemid 47235311)
2. Sugino, A., Peebles, C. L., Kreuzer, K. N. & Cozzarelli, N. R. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl Acad. Sci. USA 74, 4767-4771 (1977). (Pubitemid 8227004)
3. Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T. & Tomizawa, J. I. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc. Natl Acad. Sci. USA 74, 4772-4776 (1977). (Pubitemid 8227005)
4. Pommier, Y., Leo, E., Zhang, H. & Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17, 421-433 (2010).
5. Staker, B. L. et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl Acad. Sci. USA 99, 15387-15392 (2002). (Pubitemid 35403944)
6. Staker, B. L. et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem. 48, 2336-2345 (2005). (Pubitemid 40516428)
7. Marchand, C. et al. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of topoisomerase I-DNA covalent complexes. Mol. Cancer Ther. 5, 287-295 (2006).
8. Pommier, Y. & Cherfils, J. Interfacial protein inhibition: a nature's paradigm for drug discovery. Trends Pharmacol. Sci. 28, 136-145 (2005).
9. Pommier, Y. & Marchand, C. Interfacial inhibitors of protein-nucleic acid interactions. Curr. Med. Chem. Anti-Canc. Agents 5, 421-429 (2005). (Pubitemid 40974814)
10. Laponogov, I. et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nature Struct. Mol. Biol. 16, 667-669 (2009).
11. Laponogov, I. et al. Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS ONE 5, 8 (2010).
12. Bax, B. D. et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466, 935-940 (2010).
13. Hare, S. et al. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl Acad. Sci. USA 107, 20057-20062 (2010).
14. Krishnan, L. et al. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc. Natl Acad. Sci. USA 107, 15910-15915 (2010).
15. Hare, S., Gupta, S. S., Valkov, E., Engelman, A. & Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464, 232-236 (2010).
16. Wu, C. C. et al. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 333, 459-462 (2011).
17. Forterre, P. in DNA Topoisomerases and Cancer (ed. Pommier, Y.) 1-52 (Springer, New York, 2012).
18. Chrencik, J. E. et al. Mechanisms of camptothecin resistance by human topoisomerase I mutations. J. Mol. Biol. 339, 773-784 (2004). (Pubitemid 38686344)
19. Koster, D. A., Palle, K., Bot, E. S. M., Bjornsti, M. A. & Dekker, N. H. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 448, 213-217 (2007). (Pubitemid 47067371)
20. Pommier, Y., Pourquier, P., Urasaki, Y., Wu, J. & Laco, G. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Updat. 2, 307-318 (1999). (Pubitemid 30070455)
21. Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E. & Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 49, 1465-1469 (1989). (Pubitemid 19088683)
22. Eng, W. K., Faucette, L., Johnson, R. K. & Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34, 755-760 (1988). (Pubitemid 19014396)
23. Nitiss, J. & Wang, J. C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl Acad. Sci. USA 85, 7501-7505 (1988).
24. Sirikantaramas, S., Yamazaki, M. & Saito, K. Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants. Proc. Natl Acad. Sci. USA 105, 6782-6786 (2008). (Pubitemid 351754584)
25. Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y. & Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell resistant to camptothecin. Cancer Res. 55, 1339-1346 (1995).
26. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nature Rev. Cancer 6, 789-802 (2006). (Pubitemid 44450467)
27. Pommier, Y. et al. Repair of topoisomerase I-mediated DNA damage. Prog. Nucleic Acid Res. Mol. Biol. 81, 179-229 (2006). (Pubitemid 44767505)
28. Capranico, G., Kohn, K. W. & Pommier, Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 18, 6611-6619 (1990).
29. Pommier, Y., Capranico, G., Orr, A. & Kohn, K. W. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res. 19, 5973-5980 (1991). (Pubitemid 21913012)
30. Chen, G. L. et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259, 13560-13566 (1984). (Pubitemid 15221834)
31. Tewey, K. M., Chen, G. L., Nelson, E. M. & Liu, L. F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259, 9182-9187 (1984). (Pubitemid 14098903)
32. Pommier, Y., Capranico, G., Orr, A. & Kohn, K. W. Distribution of topoisomerase II cleavage sites in SV40 DNA and the effects of drugs. J. Mol. Biol. 222, 909-924 (1991). (Pubitemid 121003479)
33. Capranico, G., Zunino, F., Kohn, K. W. & Pommier, Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 29, 562-569 (1990). (Pubitemid 20037665)
34. Capranico, G., De Isabella, P., Tinelli, S., Bigioni, S. & Zunino, F. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry 32, 3032-3048 (1993).
35. Heddle, J. G., Barnard, F. M., Wentzell, L. M. & Maxwell, A. The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action. Nucleosides Nucleotides Nucleic Acids 19, 1249-1264 (2000).
36. De Jonge, N. et al. Rejuvenation of CcdB-poisoned gyrase by an intrinsically disordered protein domain. Mol. Cell 35, 154-163 (2009).
37. Williams, J. J. & Hergenrother, P. J. Exposing plasmids as the Achilles' heel of drug-resistant bacteria. Curr. Opin. Chem. Biol. 12, 389-399 (2008).
38. Dao-Thi, M. H. et al. Molecular basis of gyrase poisoning by the addiction toxin CcdB. J. Mol. Biol. 348, 1091-1102 (2005).
39. Ishida, R. et al. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J. Cell Biol. 126, 1341-1351 (1994). (Pubitemid 24284601)
40. Andoh, T. & Ishida, R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta 1400, 155-171 (1998). (Pubitemid 28475101)
41. Classen, S., Olland, S. & Berger, J. M. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc. Natl Acad. Sci. USA 100, 10629-10634 (2003). (Pubitemid 37140080)
42. Dumontet, C. & Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nature Rev. Drug Discov. 9, 790-803 (2010).
43. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nature Rev. Cancer 4, 253-265 (2004). (Pubitemid 38525281)
44. Gigant, B. et al. Structural basis for the regulation of tubulin by vinblastine. Nature 435, 519-522 (2005). (Pubitemid 40734250)
45. Hare, S. et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol. Pharmacol. 80, 565-572 (2011).
46. Marchand, C., Maddali, K., Metifiot, M. & Pommier, Y. HIV-1 IN inhibitors: 2010 update and perspectives. Curr. Top. Med. Chem. 9, 1016-1037 (2009).
47. Metifiot, M., Marchand, C., Maddali, K. & Pommier, Y. Resistance to integrase inhibitors. Viruses 2, 1347-1366 (2010).
48. Metifiot, M. et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 25, 1175-1178 (2011).
49. Pommier, Y., Johnson, A. & Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nature Rev. Drug Discov. 4, 236-248 (2005). (Pubitemid 40372557)
50. Li, X., Krishnan, L., Cherepanov, P. & Engelman, A. Structural biology of retroviral DNA integration. Virology 411, 194-205 (2011).
51. Zhao, X. Z. et al. Development of tricyclic hydroxy-1H-pyrrolopyridine- trione containing HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 21, 2986-2990 (2011).
52. Wells, J. A. & McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009 (2007). (Pubitemid 350273630)
53. Changeux, J. P. & Taly, A. Nicotinic receptors, allosteric proteins and medicine. Trends Mol. Med. 14, 93-102 (2008).
54. Burgin, A. B. et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nature Biotech. 28, 63-70 (2010).
55. Changeux, J.-P. 50th anniversary of the word "allosteric". Protein Science 20, 1119-1124 (2011).
56. Monod, J., Changeux, J. P. & Jacob, F. Allosteric proteins and cellular control systems. J. Mol. Biol. 6, 306-329 (1963).
57. Pommier, Y. et al. DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the carribean tunicate Ecteinascidia Turbinata. Biochemistry 35, 13303-13309 (1996). (Pubitemid 26349423)
58. Koshland, D. E. Jr, Nemethy, G. & Filmer, D. Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5, 365-385 (1966).
59. Maertens, G. N., Hare, S. & Cherepanov, P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 468, 326-329 (2010).
60. Brueckner, F. & Cramer, P. Structural basis of transcription inhibition by α-amanitin and implications for RNA polymerase II translocation. Nature Struct. Mol. Biol. 15, 811-818 (2008).
61. Bushnell, D. A., Cramer, P. & Kornberg, R. D. Structural basis of transcription: α-amanitin-RNA polymerase II cocrystal at 2.8 Ε resolution. Proc. Natl Acad. Sci. USA 99, 1218-1222 (2002). (Pubitemid 34136473)
62. Hibbs, R. E. et al. Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal α7 nicotinic acetylcholine receptor. EMBO J. 28, 3040-3051 (2009).
63. Nury, H. et al. X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. Nature 469, 428-431 (2011).
64. Sigel, E. & Luscher, B. P. A closer look at the high affinity benzodiazepine binding site on GABAA receptors. Curr. Top. Med. Chem. 11, 241-246 (2011).
65. Renault, L., Guibert, B. & Cherfils, J. Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor. Nature 426, 525-530 (2003). (Pubitemid 37522634)
66. Mossessova, E., Corpina, R. A. & Goldberg, J. Crystal structure of ARF1• Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism. Mol. Cell 12, 1403-1411 (2003). (Pubitemid 38037010)
67. Ravelli, R. B. G. et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428, 198-202 (2004). (Pubitemid 38374318)
68. Jin, L. & Harrison, S. C. Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc. Natl Acad. Sci. USA 99, 13522-13526 (2002). (Pubitemid 35215414)
69. Huai, Q. et al. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc. Natl Acad. Sci. USA 99, 12037-12042 (2002).
70. Roca, J., Ishida, R., Berger, J. M., Andoh, T. & Wang, J. C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl Acad. Sci. USA 91, 1781-1785 (1994). (Pubitemid 24080289)
71. Takebayashi, Y. et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nature Med. 7, 961-966 (2001). (Pubitemid 32756435)
72. Nettles, J. H. et al. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 305, 866-869 (2004). (Pubitemid 39038421)
73. Kissinger, C. R. et al. Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 378, 641-644 (1995).
74. Griffith, J. P. et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82, 507-522 (1995).
75. Tesmer, J. J., Sunahara, R. K., Gilman, A. G. & Sprang, S. R. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsα•GTPγS. Science 278, 1907-1916 (1997). (Pubitemid 28013225)
76. Wurtele, M., Jelich-Ottmann, C., Wittinghofer, A. & Oecking, C. Structural view of a fungal toxin acting on a 14-3-3 regulatory complex. EMBO J. 22, 987-994 (2003). (Pubitemid 36313583)
77. Agrawal, R. K. & Frank, J. Structural studies of the translational apparatus. Curr. Opin. Struct. Biol. 9, 215-221 (1999). (Pubitemid 29452901)
78. Laurberg, M. et al. Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site. J. Mol. Biol. 303, 593-603 (2000).
79. Ioanoviciu, A. et al. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J. Med. Chem. 48, 4803-4814 (2005). (Pubitemid 41033123)
80. Choi, J., Chen, J., Schreiber, S. L. & Clardy, J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239-242 (1996). (Pubitemid 26285890)
81. Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182-188 (2009).
82. Edwards, M. J. et al. A crystal structure of the bifunctional antibiotic simocyclinone D8, bound to DNA gyrase. Science 326, 1415-1418 (2009).
83. Snyder, J. P., Nettles, J. H., Cornett, B., Downing, K. H. & Nogales, E. The binding conformation of taxol in β-tubulin: a model based on electron crystallographic density. Proc. Natl Acad. Sci. USA 98, 5312-5316 (2001). (Pubitemid 32397125)
84. Bowen, W. S., Van Dyke, N., Murgola, E. J., Lodmell, J. S. & Hill, W. E. Interaction of thiostrepton and elongation factor-G with the ribosomal protein L11-binding domain. J. Biol. Chem. 280, 2934-2943 (2004).